Literature DB >> 9138159

Alport's syndrome.

F Flinter1.   

Abstract

Alport's syndrome (AS) is a progressive glomerulonephritis which is associated with high tone sensorineural deafness and characteristic eye signs. It accounts for 0.6% of all patients who start renal replacement therapy in Europe, and is most commonly inherited as an X linked disorder with a gene frequency of 1 in 5000. During the last six years several type IV collagen genes have been implicated in the aetiology of AS, and mutation detection studies are enabling genotype/phenotype correlations to be made, as well as facilitating carrier detection and prenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138159      PMCID: PMC1050922          DOI: 10.1136/jmg.34.4.326

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  41 in total

1.  Hereditary nephropathy with nerve deafness (Alport's syndrome).

Authors:  A C Ferguson; C P Rance
Journal:  Am J Dis Child       Date:  1972-07

2.  Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome.

Authors:  S L Hostikka; R L Eddy; M G Byers; M Höyhtyä; T B Shows; K Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  X-linked inheritance of Alport syndrome: family P revisited.

Authors:  S J Hasstedt; C L Atkin
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

4.  Isolation of a collagen from basement membranes containing three identical - chains.

Authors:  N A Kefalides
Journal:  Biochem Biophys Res Commun       Date:  1971-10-01       Impact factor: 3.575

Review 5.  Hereditary disorders of the glomerular basement membrane.

Authors:  H J Smeets; V V Knoers; L P van de Heuvel; H H Lemmink; C H Schröder; L A Monnens
Journal:  Pediatr Nephrol       Date:  1996-12       Impact factor: 3.714

6.  Characteristic ultrastructural lesion of the glomerular basement membrane in progressive hereditary nephritis (Alport's syndrome).

Authors:  N Hinglais; J P Grünfeld; E Bois
Journal:  Lab Invest       Date:  1972-11       Impact factor: 5.662

7.  Reversal of deafness after renal transplantation in Alport's syndrome.

Authors:  T J McDonald; H Zincke; C F Anderson; N T Ott
Journal:  Laryngoscope       Date:  1978-01       Impact factor: 3.325

8.  Alport's syndrome of hereditary nephritis with deafness.

Authors:  D A WILLIAMSON
Journal:  Lancet       Date:  1961-12-16       Impact factor: 79.321

Review 9.  Variants of Alport's syndrome.

Authors:  J P Grünfeld; G Grateau; L H Noel; R Charbonneau; M C Gubler; C O Savage; C M Lockwood
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

10.  X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene.

Authors:  A Renieri; M Bruttini; L Galli; P Zanelli; T Neri; S Rossetti; A Turco; N Heiskari; J Zhou; R Gusmano; L Massella; G Banfi; F Scolari; A Sessa; G Rizzoni; K Tryggvason; P F Pignatti; M Savi; A Ballabio; M De Marchi
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

View more
  21 in total

Review 1.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

2.  Antigen retrieval with protease digestion applied in immunohistochemical diagnosis of Alport syndrome.

Authors:  Na Guan; Li-Xia Yu; Guo-Hong Wu; Yan Xing; Jie Ding
Journal:  Nephrol Dial Transplant       Date:  2008-06-03       Impact factor: 5.992

3.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

4.  Alport syndrome in a Kazakh family: a case study.

Authors:  Elena V Zholdybayeva; Saule E Rakhimova; Barshagul T Baikara; Nazym B Nigmatullina; Nagima M Mustapayeva; Kuvat T Momynaliev
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

5.  Medical genetics: 3. An approach to the adult with a genetic disorder.

Authors:  Dawna M Gilchrist
Journal:  CMAJ       Date:  2002-10-29       Impact factor: 8.262

6.  Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2.

Authors:  Vera Uliana; Elena Marcocci; Mafalda Mucciolo; Ilaria Meloni; Claudia Izzi; Carlo Manno; Mirella Bruttini; Francesca Mari; Francesco Scolari; Alessandra Renieri; Leonardo Salviati
Journal:  Pediatr Nephrol       Date:  2010-12-14       Impact factor: 3.714

7.  Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.

Authors:  D Cosgrove; K Rodgers; D Meehan; C Miller; K Bovard; A Gilroy; H Gardner; V Kotelianski; P Gotwals; A Amatucci; R Kalluri
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

8.  The importance of non-invasive genetic analysis in the initial diagnostics of Alport syndrome in young patients.

Authors:  Maja Slajpah; Anamarija Meglic; Polonca Furlan; Damjan Glavac
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

9.  Advances in Alport syndrome diagnosis using next-generation sequencing.

Authors:  Rosangela Artuso; Chiara Fallerini; Laura Dosa; Francesca Scionti; Maurizio Clementi; Guido Garosi; Laura Massella; Maria Carmela Epistolato; Roberta Mancini; Francesca Mari; Ilaria Longo; Francesca Ariani; Alessandra Renieri; Mirella Bruttini
Journal:  Eur J Hum Genet       Date:  2011-09-07       Impact factor: 4.246

10.  Ventricular septal defect in a child with Alport syndrome: a case report.

Authors:  Pier Paolo Bassareo; Andrea Raffaele Marras; Giuseppe Mercuro
Journal:  BMC Cardiovasc Disord       Date:  2010-10-05       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.